对DA-EPOCH-R方案的反应与新诊断的双打击和三打击高级别B细胞淋巴瘤患者中“更健康”的细胞毒性T细胞的激活有关。 - Suppr

Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.

作者信息

De Jonge A Vera, Bruins Wassilis S C, Duetz Carolien, Korst Charlotte L B M, Rentenaar Rosa, Cosovic Meliha, Eken Merve, Kersten Marie-Jose, Sandberg Yorick, Van Rijn Rozemarijn S, Fijnheer Rob, Mutsaers Pim, Vergote Vibeke K J, Issa Djamila, Beeker Aart, Bilgin Yavuz M, Visser Otto, Van Werkhoven Erik, Roemer Margaretha G M, Chamuleau Martine E D, Mutis Tuna

机构信息

Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam.

Department of Internal Medicine, Maasstad Hospital, Rotterdam.

出版信息

Haematologica. 2024 Nov 1;109(11):3760-3765. doi: 10.3324/haematol.2024.285170.

DOI:10.3324/haematol.2024.285170

PMID:38961740

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11532709/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5799/11532709/5ede151d1953/1093760.fig1.jpg

相似文献

Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.

Haematologica. 2024 Nov 1;109(11):3760-3765. doi: 10.3324/haematol.2024.285170.

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens.

Blood Lymphat Cancer. 2019 Aug 19;9:33-43. doi: 10.2147/BLCTT.S216292. eCollection 2019.

A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.

Leuk Lymphoma. 2023 Jan;64(1):107-118. doi: 10.1080/10428194.2022.2140281. Epub 2022 Nov 2.

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with , gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study.

Cancer Manag Res. 2019 Feb 11;11:1363-1372. doi: 10.2147/CMAR.S192143. eCollection 2019.

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

Leuk Res Rep. 2021 Nov 29;16:100284. doi: 10.1016/j.lrr.2021.100284. eCollection 2021.

CODOX-M/IVAC-R DA-EPOCH-R in double-hit/triple-hit lymphoma patients aged 60 years or under.

Haematologica. 2025 Feb 1;110(2):448-456. doi: 10.3324/haematol.2024.286168.

Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.

Cancer Med. 2021 Dec;10(24):8866-8875. doi: 10.1002/cam4.4387. Epub 2021 Nov 24.

DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction.

J Clin Exp Hematop. 2021 Mar 18;61(1):42-47. doi: 10.3960/jslrt.20043. Epub 2021 Feb 6.

R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.

Lancet Haematol. 2023 Dec;10(12):e966-e975. doi: 10.1016/S2352-3026(23)00279-X. Epub 2023 Oct 31.

[Successful treatment with dose-adjusted EPOCH-R for triple-hit lymphoma having BCL2, BCL6 and MYC translocations].

Rinsho Ketsueki. 2015 Jul;56(7):905-10. doi: 10.11406/rinketsu.56.905.

本文引用的文献

Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.

Blood Adv. 2024 Mar 12;8(5):1094-1104. doi: 10.1182/bloodadvances.2023011687.

Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy.

Cancer Cell Int. 2021 May 27;21(1):282. doi: 10.1186/s12935-021-01978-w.

Lingering effects of chemotherapy on mature T cells impair proliferation.

Blood Adv. 2020 Oct 13;4(19):4653-4664. doi: 10.1182/bloodadvances.2020001797.

HLA-DR-expressing NK cells: Effective killers suspected for antigen presentation.

J Leukoc Biol. 2021 Feb;109(2):327-337. doi: 10.1002/JLB.3RU0420-668RR. Epub 2020 May 18.

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Lancet Haematol. 2018 Dec;5(12):e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.

Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.

Br J Haematol. 2015 Aug;170(4):504-14. doi: 10.1111/bjh.13463. Epub 2015 Apr 24.

Ifosfamide and cyclophosphamide: effects on immunosurveillance.

Oncology. 2003;65 Suppl 2:17-20. doi: 10.1159/000073353.

Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model.

Cancer Immunol Immunother. 2002 Jan;50(11):588-96. doi: 10.1007/s00262-001-0237-3. Epub 2001 Nov 16.

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

N Engl J Med. 2002 Jan 24;346(4):235-42. doi: 10.1056/NEJMoa011795.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.

作者信息

机构信息

出版信息

相似文献

本文引用的文献